CN1331500C - 治疗阴虚肝旺、热伤络脉所致的眼底出血的中药及制备方法 - Google Patents
治疗阴虚肝旺、热伤络脉所致的眼底出血的中药及制备方法 Download PDFInfo
- Publication number
- CN1331500C CN1331500C CNB2004100732345A CN200410073234A CN1331500C CN 1331500 C CN1331500 C CN 1331500C CN B2004100732345 A CNB2004100732345 A CN B2004100732345A CN 200410073234 A CN200410073234 A CN 200410073234A CN 1331500 C CN1331500 C CN 1331500C
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- liver
- chinese medicine
- yin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 210000004185 liver Anatomy 0.000 title abstract description 20
- 208000032843 Hemorrhage Diseases 0.000 title abstract description 19
- 208000031971 Yin Deficiency Diseases 0.000 title abstract description 5
- 241001601725 Sthenias Species 0.000 title 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 claims abstract description 36
- 208000013403 hyperactivity Diseases 0.000 claims abstract description 19
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 17
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 17
- 230000007812 deficiency Effects 0.000 claims description 20
- 206010053615 Thermal burn Diseases 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 9
- 241000207929 Scutellaria Species 0.000 claims description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 241001529739 Prunella <angiosperm> Species 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000002791 Panax Nutrition 0.000 claims description 3
- 241000208343 Panax Species 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000012567 medical material Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 241001421953 Eclipta <beetle> Species 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 37
- 210000004369 blood Anatomy 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 22
- 230000004438 eyesight Effects 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 10
- 210000003734 kidney Anatomy 0.000 abstract description 8
- 230000017531 blood circulation Effects 0.000 abstract description 7
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 abstract description 6
- 244000286838 Eclipta prostrata Species 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 210000004072 lung Anatomy 0.000 abstract description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 abstract description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 abstract description 2
- UOZDOLIXBYLRAC-UHFFFAOYSA-L [2-hydroxy-3-(trimethylazaniumyl)propyl]-trimethylazanium;diiodide Chemical compound [I-].[I-].C[N+](C)(C)CC(O)C[N+](C)(C)C UOZDOLIXBYLRAC-UHFFFAOYSA-L 0.000 abstract description 2
- 238000001816 cooling Methods 0.000 abstract description 2
- 229960002897 heparin Drugs 0.000 abstract description 2
- 229920000669 heparin Polymers 0.000 abstract description 2
- 229960005436 inositol nicotinate Drugs 0.000 abstract description 2
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 abstract description 2
- 229960004839 potassium iodide Drugs 0.000 abstract description 2
- JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 abstract description 2
- 229960002312 tolazoline Drugs 0.000 abstract description 2
- 229960005356 urokinase Drugs 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract 4
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract 2
- 240000007890 Leonurus cardiaca Species 0.000 abstract 2
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract 2
- 241000830535 Ligustrum lucidum Species 0.000 abstract 2
- 241000736199 Paeonia Species 0.000 abstract 2
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 2
- 244000179560 Prunella vulgaris Species 0.000 abstract 2
- 240000007164 Salvia officinalis Species 0.000 abstract 2
- 235000005272 common selfheal Nutrition 0.000 abstract 2
- 235000005412 red sage Nutrition 0.000 abstract 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 241000293050 Entodon Species 0.000 abstract 1
- 235000003365 Ilex pubescens Nutrition 0.000 abstract 1
- 241001100932 Ilex pubescens Species 0.000 abstract 1
- 240000005001 Paeonia suffruticosa Species 0.000 abstract 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 28
- 230000003287 optical effect Effects 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 15
- 210000004204 blood vessel Anatomy 0.000 description 11
- 238000012800 visualization Methods 0.000 description 10
- 230000008859 change Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 241000201295 Euphrasia Species 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 206010047513 Vision blurred Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 206010013781 dry mouth Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 206010013954 Dysphoria Diseases 0.000 description 3
- 201000010183 Papilledema Diseases 0.000 description 3
- 206010033708 Papillitis Diseases 0.000 description 3
- 206010057267 Periphlebitis Diseases 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 206010029410 night sweats Diseases 0.000 description 3
- 230000036565 night sweats Effects 0.000 description 3
- 201000002166 optic papillitis Diseases 0.000 description 3
- 208000001297 phlebitis Diseases 0.000 description 3
- 208000004644 retinal vein occlusion Diseases 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000083513 Punctum Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 206010038491 Renal papillary necrosis Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000002189 macula lutea Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229950002100 prolonium iodide Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
项目 | 指标 | 病例数(N) | X±SD |
年龄 | 18-65岁 | 300 | 48.90±19.73 |
病程 | 12天-8个月 | 300 | 5.54±4.58 |
患眼病只数 | 右眼左眼双眼 | 11710281 |
组别 | 例数(N) | 临床治愈(%) | 显效(%) | 有效(%) | 无效(%) | 总有效率(%) |
验证组 | 300 | 65(21.67) | 127(42.33) | 86(28.67) | 22(7.33) | 92.67 |
对照组 | 100 | 18(18.00) | 39(39.00) | 31(31.00) | 12(12.00) | 88.00 |
U=1.39 | P>0.05 |
疾病分类 | 治愈只数(%) | 显效只数(%) | 有效只数(%) | 无效只数(%) | 总有效率(%) |
视网膜静脉阻塞 | 10(12.35) | 27(33.33) | 31(38.27) | 13(16.05) | 83.95 |
视网膜静脉周围炎 | 14(14.89) | 30(31.92) | 35(37.23) | 15(15.96) | 84.04 |
中渗 | 4(15.38) | 11(42.31) | 7(26.92) | 4(15.38) | 84.62 |
糖网病 | |||||
玻璃体出血 | 4(12.12) | 12(36.36) | 11(33.33) | 6(18.18) | 81.82 |
视盘血管炎 | 6(15.38) | 12(30.77) | 13(33.33) | 8(20.51) | 78.49 |
黄斑出血 | 9(11.11) | 26(32.10) | 29(35.80) | 17(20.99) | 79.01 |
症状 | 例数(n) | 治疗前总积分 | 治疗后总积分 | 改善率(%) |
眼底出血 | 300 | 1306 | 264 | 79.79 |
视物昏花 | 232 | 676 | 156 | 76.92 |
头晕耳鸣 | 189 | 572 | 126 | 77.97 |
潮热盗汗 | 216 | 604 | 144 | 76.16 |
口干咽燥 | 202 | 636 | 154 | 75.79 |
五心烦热 | 213 | 612 | 129 | 78.92 |
口干欲饮 | 226 | 418 | 67 | 83.97 |
大便干结 | 138 | 278 | 69 | 75.18 |
尿少色黄 | 152 | 294 | 56 | 80.95 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100732345A CN1331500C (zh) | 2004-11-04 | 2004-11-04 | 治疗阴虚肝旺、热伤络脉所致的眼底出血的中药及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100732345A CN1331500C (zh) | 2004-11-04 | 2004-11-04 | 治疗阴虚肝旺、热伤络脉所致的眼底出血的中药及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1768802A CN1768802A (zh) | 2006-05-10 |
CN1331500C true CN1331500C (zh) | 2007-08-15 |
Family
ID=36750507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100732345A Active CN1331500C (zh) | 2004-11-04 | 2004-11-04 | 治疗阴虚肝旺、热伤络脉所致的眼底出血的中药及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1331500C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107789430A (zh) * | 2016-09-06 | 2018-03-13 | 王保安 | 一种中药组合物在制备预防/治疗黄斑变性疾病药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1451422A (zh) * | 2003-05-21 | 2003-10-29 | 西安碑林药业股份有限公司 | 一种治疗眼底出血症的中药及其制备方法 |
-
2004
- 2004-11-04 CN CNB2004100732345A patent/CN1331500C/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1451422A (zh) * | 2003-05-21 | 2003-10-29 | 西安碑林药业股份有限公司 | 一种治疗眼底出血症的中药及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1768802A (zh) | 2006-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1985984A (zh) | 一种用于治疗神经症的药物组合物 | |
CN100381154C (zh) | 治疗眼病的中药组合物及其制备方法 | |
CN112138046A (zh) | 一种治疗干眼症、视疲劳的药物组合物及其制备方法和用途 | |
CN102210841B (zh) | 治疗中心性浆液性脉络膜视网膜病变的中药制剂 | |
CN105055785A (zh) | 一种治疗糖尿病视网膜病变的中药组合物 | |
CN1331500C (zh) | 治疗阴虚肝旺、热伤络脉所致的眼底出血的中药及制备方法 | |
CN107648397B (zh) | 一种用于治疗肝肾阴虚型的中药组合物及其制备方法和应用 | |
CN113648351A (zh) | 一种中药组合物在制备预防/治疗黄斑变性疾病药物中的应用 | |
CN102824506B (zh) | 治疗再生障碍性贫血的中药制剂 | |
CN108079184B (zh) | 中药组合物在制备防治糖尿病视网膜病变药物中的应用 | |
CN103908627A (zh) | 治疗视网膜中央静脉阻塞的中药制剂 | |
CN105213887A (zh) | 一种用于治疗青光眼的中药组合物 | |
CN1857531A (zh) | 一种治疗糖尿病视网膜病变的中药制剂处方、制备方法及其应用 | |
CN103830495A (zh) | 一种治疗糖尿病性视网膜病变所致眼底出血的中药组合物及其制备方法 | |
CN104324139B (zh) | 一种治疗干眼症的药物组合物 | |
CN104306579B (zh) | 一种治疗阴虚血瘀型糖尿病视网膜病变的中药及其制备方法与应用 | |
CN106581445A (zh) | 一种治疗糖尿病视网膜病变的中药配方 | |
CN105833064A (zh) | 用于治疗糖尿病视网膜病变的明目汤剂 | |
CN105031546A (zh) | 一种预防和治疗糖尿病视网膜病变的中药及其制备方法 | |
CN105288290A (zh) | 一种防治视瞻昏渺的中药的制备方法 | |
CN104857270A (zh) | 一种治疗糖尿病黄斑水肿的中药 | |
CN104940396B (zh) | 一种降低激素耐药型肾病综合征患者对激素抵抗性的药物 | |
CN104042894A (zh) | 一种治疗视神经萎缩的药物及其制备方法 | |
CN104623282A (zh) | 一种用于调理高血压的中药保健制剂 | |
CN102028811B (zh) | 一种治疗消渴病的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicine for treating ocular funcus hemorrhage caused by yin deficiency, liver sthenia, heat impairing collaterals and preparation method Effective date of registration: 20160928 Granted publication date: 20070815 Pledgee: Xianyang Rural Commercial Bank of Shaanxi Qin Limited by Share Ltd Pledgor: Wang Baoan Registration number: 2016610000042 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200427 Granted publication date: 20070815 Pledgee: Xianyang Rural Commercial Bank of Shaanxi Qin Limited by Share Ltd Pledgor: Wang Baoan Registration number: 2016610000042 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Chinese medicine for treating ocular funcus hemorrhage caused by yin deficiency, liver sthenia, heat impairing collaterals and preparation method Effective date of registration: 20200428 Granted publication date: 20070815 Pledgee: Xianyang Rural Commercial Bank of Shaanxi Qin Limited by Share Ltd Pledgor: Wang Baoan Registration number: Y2020990000396 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220530 Granted publication date: 20070815 Pledgee: Xianyang Rural Commercial Bank of Shaanxi Qin Limited by Share Ltd. Pledgor: Wang Baoan Registration number: Y2020990000396 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Traditional Chinese medicine for treating eyeground hemorrhage caused by Yin deficiency, liver hyperactivity and collateral vessel heat injury and its preparation method Effective date of registration: 20220606 Granted publication date: 20070815 Pledgee: Xianyang Rural Commercial Bank of Shaanxi Qin Limited by Share Ltd. Pledgor: Wang Baoan Registration number: Y2022980007094 |